Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | apoferritin-2 | 0.001 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | bacterioferritin/cytochrome b1 | 0.001 | 0.5 | 0.5 |
Echinococcus granulosus | ferritin | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin light chain | 0.001 | 0.5 | 0.5 |
Mycobacterium ulcerans | bacterioferritin BfrB | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin | 0.001 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable bacterioferritin BfrA | 0.001 | 0.5 | 0.5 |
Mycobacterium ulcerans | bacterioferritin BfrA | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin | 0.001 | 0.5 | 0.5 |
Echinococcus multilocularis | ferritin | 0.001 | 0.5 | 0.5 |
Treponema pallidum | bacterioferrin (TpF1) | 0.001 | 0.5 | 0.5 |
Echinococcus multilocularis | expressed protein | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin light chain | 0.001 | 0.5 | 0.5 |
Trichomonas vaginalis | ferritin, putative | 0.001 | 0.5 | 0.5 |
Mycobacterium leprae | PROBABLE BACTERIOFERRITIN BFRA | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | apoferritin-2 | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin | 0.001 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Bacterioferritin BfrB | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin | 0.001 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (binding) | = 11.2202 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.